NASDAQ:KYMR

Kymera Therapeutics Competitors

$38.66
+0.10 (+0.26 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$37.07
Now: $38.66
$38.79
50-Day Range
$31.08
MA: $44.38
$60.04
52-Week Range
$25.43
Now: $38.66
$91.92
Volume482,865 shs
Average Volume326,153 shs
Market Capitalization$1.73 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Kymera Therapeutics (NASDAQ:KYMR) Vs. TWST, DNLI, HALO, ADPT, KOD, and VIR

Should you be buying KYMR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Kymera Therapeutics, including Twist Bioscience (TWST), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), and Vir Biotechnology (VIR).

Kymera Therapeutics (NASDAQ:KYMR) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Kymera Therapeutics and Twist Bioscience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02502.71
Twist Bioscience11302.40

Kymera Therapeutics presently has a consensus price target of $48.6667, indicating a potential upside of 25.88%. Twist Bioscience has a consensus price target of $137.50, indicating a potential downside of 0.56%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kymera Therapeutics is more favorable than Twist Bioscience.

Valuation & Earnings

This table compares Kymera Therapeutics and Twist Bioscience's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Twist Bioscience$90.10 million74.66$-139,930,000.00($3.00)-46.09

Kymera Therapeutics has higher earnings, but lower revenue than Twist Bioscience.

Profitability

This table compares Kymera Therapeutics and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Twist Bioscience-155.31%-44.62%-35.49%

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Kymera Therapeutics beats Twist Bioscience on 6 of the 9 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Earnings & Valuation

This table compares Denali Therapeutics and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million246.41$-197,610,000.00($2.07)-26.25
Kymera TherapeuticsN/AN/AN/AN/AN/A

Kymera Therapeutics has lower revenue, but higher earnings than Denali Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and target prices for Denali Therapeutics and Kymera Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01702.88
Kymera Therapeutics02502.71

Denali Therapeutics currently has a consensus price target of $75.8571, suggesting a potential upside of 39.60%. Kymera Therapeutics has a consensus price target of $48.6667, suggesting a potential upside of 25.88%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Denali Therapeutics and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
Kymera TherapeuticsN/AN/AN/A

Summary

Denali Therapeutics beats Kymera Therapeutics on 6 of the 9 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Profitability

This table compares Kymera Therapeutics and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Halozyme Therapeutics10.78%24.29%4.08%

Valuation and Earnings

This table compares Kymera Therapeutics and Halozyme Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Halozyme Therapeutics$195.99 million33.79$-72,240,000.00($0.50)-92.44

Kymera Therapeutics has higher earnings, but lower revenue than Halozyme Therapeutics.

Institutional & Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 2.6% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Kymera Therapeutics and Halozyme Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02502.71
Halozyme Therapeutics01902.90

Kymera Therapeutics currently has a consensus price target of $48.6667, suggesting a potential upside of 25.88%. Halozyme Therapeutics has a consensus price target of $42.9167, suggesting a potential downside of 7.15%. Given Kymera Therapeutics' higher probable upside, research analysts clearly believe Kymera Therapeutics is more favorable than Halozyme Therapeutics.

Summary

Halozyme Therapeutics beats Kymera Therapeutics on 8 of the 9 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are held by institutional investors. 22.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Kymera Therapeutics and Adaptive Biotechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02502.71
Adaptive Biotechnologies02402.67

Kymera Therapeutics presently has a consensus target price of $48.6667, suggesting a potential upside of 25.88%. Adaptive Biotechnologies has a consensus target price of $61.40, suggesting a potential upside of 46.71%. Given Adaptive Biotechnologies' higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Kymera Therapeutics.

Valuation & Earnings

This table compares Kymera Therapeutics and Adaptive Biotechnologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Adaptive Biotechnologies$85.07 million68.49$-68,610,000.00($1.01)-41.44

Kymera Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies.

Profitability

This table compares Kymera Therapeutics and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Adaptive Biotechnologies-132.32%-20.15%-13.09%

Summary

Kymera Therapeutics beats Adaptive Biotechnologies on 5 of the 9 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Profitability

This table compares Kodiak Sciences and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
Kymera TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

82.3% of Kodiak Sciences shares are held by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are held by institutional investors. 39.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Kodiak Sciences and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-91.91
Kymera TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Kodiak Sciences and Kymera Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences17402.25
Kymera Therapeutics02502.71

Kodiak Sciences presently has a consensus target price of $129.9091, suggesting a potential upside of 14.39%. Kymera Therapeutics has a consensus target price of $48.6667, suggesting a potential upside of 25.88%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Kodiak Sciences.

Summary

Kymera Therapeutics beats Kodiak Sciences on 5 of the 7 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Vir Biotechnology and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
Kymera TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Vir Biotechnology and Kymera Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
Kymera Therapeutics02502.71

Vir Biotechnology currently has a consensus price target of $66.00, suggesting a potential upside of 43.73%. Kymera Therapeutics has a consensus price target of $48.6667, suggesting a potential upside of 25.88%. Given Vir Biotechnology's higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Kymera Therapeutics.

Institutional & Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vir Biotechnology and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million726.46$-174,680,000.00($5.76)-7.97
Kymera TherapeuticsN/AN/AN/AN/AN/A

Kymera Therapeutics has lower revenue, but higher earnings than Vir Biotechnology.


Kymera Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Twist Bioscience logo
TWST
Twist Bioscience
1.2$138.28+2.7%$6.91 billion$90.10 million-36.87Insider Selling
Analyst Revision
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$54.34+3.1%$6.78 billion$26.68 million-24.59
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.22+0.0%$6.62 billion$195.99 million288.88Insider Selling
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$41.85+2.8%$5.99 billion$85.07 million-44.05
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$114.89+0.7%$5.88 billionN/A-49.52
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.92+1.9%$5.76 billion$8.09 million-19.46Analyst Downgrade
Insider Selling
News Coverage
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26+0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.44+1.3%$4.62 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.69+1.5%$4.54 billion$20,000.00-5.17
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14+1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$71.44+3.0%$3.60 billionN/A-41.06Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01+1.6%$3.25 billion$125.57 million-42.70Insider Selling
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.39+4.1%$3.05 billionN/A0.00News Coverage
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32+3.1%$2.96 billion$50.04 million0.00
Vericel logo
VCEL
Vericel
1.1$58.62+1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67+18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49+0.7%$2.10 billion$31.43 million-5.13Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.94+2.7%$2.00 billion$44.67 million-2.64
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.24+0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85+0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$17.26+4.7%$1.89 billion$40,000.00-24.31
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33+0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48+2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42+3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48+4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51+3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.23+2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08+2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84+4.5%$1.42 billion$7.80 million-17.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55+1.1%$1.40 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.55+6.7%$1.34 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89+1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24+5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89+4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50+2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37+7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77+0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39+1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.41+5.9%$1.00 billionN/A0.00Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01+6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.01+0.8%$911.40 millionN/A-4.13Insider Selling
Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17+1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86+4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86+6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88+8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71+2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.13+0.9%$825.65 million$22.99 million-10.18
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25+3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93+2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02+5.3%$744.64 million$2.51 million-3.65
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.